Swedish Orphan Biovitrum AB (0MTD)
London Exchange · UK · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 435.60 |
|---|---|
| 52-week range | 305.20 – 486.40 |
| Return, 1 month / 3 months | −3.2% / −6.4% |
| Return, 1 year / 3 years | +42.4% / +106.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 48 |
| Volatility (1 year) | 26.0% |
| Worst drawdown (1 year) | -15.6% |
| Average daily value traded | 46.62M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a specialty biopharmaceutical company based in Sweden. It develops and supplies medicines for people with rare diseases, with a particular focus on haemophilia and other bleeding disorders, and it also provides treatments in immunology and inflammation. Its customers are mainly healthcare providers, hospitals and specialist clinics that care for patients with these uncommon conditions, and its products are used across European and other international markets.
On this site Swedish Orphan Biovitrum AB appears as a stock on the London Exchange (UK), code 0MTD, with prices in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Swedish Orphan Biovitrum AB (0MTD) trades on the London Exchange in UK. It last closed at SEK 435.60 on 19 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 466 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 42.4% and over the last three months it fell 6.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 65 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.5% | ||
| From 52-week high | -9.8% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -6.4% | ||
| 6-month return | 5.3% | ||
| 12-month return, skipping the last month | 47.2% | ||
| Stability (higher is calmer) | 79 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.6% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 46.62M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +0.6% |
|---|---|
| 1 month | −3.2% |
| 3 months | −6.4% |
| 6 months | +5.3% |
| 1 year | +42.4% |
| 3 years | +106.1% |
| 5 years | +95.2% |
Signals
| 50-day / 200-day average | 445.84 / 420.96 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 9.54 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.